Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genetic and metabolic determinants of statin efficacy and tolerability
2017-002898-19Phase 4Completed
- Sponsor
- Helsinki University Hospital
- Start
- Dec 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ulinastatin in atherosclerotic disease, sponsored by Helsinki University Hospital. Primary endpoint: % change in LDL cholesterol levels (ΔLDL%). Started Dec 2017; status: completed.
02
Drugs
ulinastatin
03
Conditions
atherosclerotic disease
Beyond the preview
Go deeper on 2017-002898-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002898-19.